CTS2190 Phase I /II Clinical Study in Patients

This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types. The study drug, CTS2190, is a PRMT1 inhibitor administered orally. The study is planned to treat up to 224 participants.

Trial Details

NCT ID
NCT06224387
Phase
PHASE1 / PHASE2
Sponsor
CytosinLab Therapeutics Co., Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • CTS2190 capsules
Locations (sample)
  • Luoyang, Henan, China|34.67345,112.43684
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Subjects who meet all of the following criteria can be included in this study:
  • Male or female ≥ 18 years of age at signing of ICF.
  • Part 1: histologically or cytologically confirmed locally advanced or metastatic solid tumors at screening who cannot be treated surgically and hav…
  • Part 2: histologically or cytologically confirmed advanced solid tumors (including pancreatic cancer, non-small cell lung cancer and/or other tumor…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →